期刊
NUTRIENTS
卷 14, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/nu14163301
关键词
capillary electrophoresis; cinnamaldehyde; curcumin; diabetes; insulin; isoelectric focusing; protein phosphatase 2; post-translational modification; serine; threonine protein kinase; tyrosine phosphatase
资金
- Roseman University ofHealth Sciences
This study found that cinnamaldehyde and curcumin can increase the phosphorylation of Akt2 at multiple sites, thereby promoting insulin signaling pathway. Inhibiting the activities of PP2A and PTP1B, cinnamaldehyde and curcumin enhance the phosphorylation of Akt2 at critical sites and improve Akt2's response to insulin. These findings provide a theoretical basis for the development of new drugs for insulin resistance syndrome.
In this study, the effects of cinnamaldehyde and curcumin on Akt2, a serine/threonine protein kinase central to the insulin signaling pathway, were examined in preadipocytes. Cinnamaldehyde or curcumin treatment increased Akt2 phosphorylation at multiple sites including T450 and Y475, but had no effect on Akt2 phosphorylation at S474, which is critical for Akt2 activation. Surprisingly, insulin treatment with cinnamaldehyde or curcumin increased p-Akt2 (S474) by 3.5-fold versus insulin treatment alone. Furthermore, combined cinnamaldehyde, curcumin, and insulin treatment increased p-Akt2 (S474) by 7-fold versus insulin treatment alone. Interestingly, cinnamaldehyde and curcumin inhibited both serine/threonine phosphatase 2A (PP2A) and protein tyrosine phosphatase 1B (PTP1B). Akt2 activation is a multistep process that requires phosphorylation at T450 for proper folding and maturation, and phosphorylation of both Y475 and S474 for stabilization of the catalytic domain. It is plausible that by inhibiting PP2A and PTP1B, cinnamaldehyde and curcumin increase phosphorylation at T450 and Y475, and prime Akt2 for insulin-stimulated phosphorylation at S474. Notably, the combination of a PP2A inhibitor, okadaic acid, and a PTP1B inhibitor increased p-Akt2 (S474), even in the absence of insulin. Future combinations of PP2A and PTP1B inhibitors provide a rational platform to engineer new therapeutics for insulin resistance syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据